These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16038645)

  • 1. Myeloid growth factors clinical practice guidelines in oncology.
    Crawford J; Althaus B; Armitage J; Blayney DW; Cataland S; Dale DC; Demetri GD; Foran J; Heaney ML; Htoy S; Kloth DD; Lyman GH; Michaud L; Motl S; Vadhan-Raj S; Wong MK;
    J Natl Compr Canc Netw; 2005 Jul; 3(4):540-55. PubMed ID: 16038645
    [No Abstract]   [Full Text] [Related]  

  • 2. Myeloid growth factors.
    Crawford J; Armitage J; Balducci L; Bennett C; Blayney DW; Cataland SR; Dale DC; Demetri GD; Erba HP; Foran J; Freifeld AG; Goemann M; Heaney ML; Htoy S; Hudock S; Kloth DD; Kuter DJ; Lyman GH; Michaud LB; Miyata SC; Tallman MS; Vadhan-Raj S; Westervelt P; Wong MK;
    J Natl Compr Canc Netw; 2009 Jan; 7(1):64-83. PubMed ID: 19176207
    [No Abstract]   [Full Text] [Related]  

  • 3. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
    Lyman GH
    J Natl Compr Canc Netw; 2005 Jul; 3(4):557-71. PubMed ID: 16038646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatment options for managing chemotherapy-induced neutropenia.
    Valley AW
    Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S11-7. PubMed ID: 12166032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESMO recommendations for the application of hematopoietic growth factors.
    Greil R; Jost LM;
    Ann Oncol; 2005; 16 Suppl 1():i80-2. PubMed ID: 15888768
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemotherapy-induced neutropenia: new approaches to an old problem.
    Ozer H
    Semin Oncol; 2003 Aug; 30(4 Suppl 13):1-2. PubMed ID: 14508713
    [No Abstract]   [Full Text] [Related]  

  • 7. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.
    Ozer H; Armitage JO; Bennett CL; Crawford J; Demetri GD; Pizzo PA; Schiffer CA; Smith TJ; Somlo G; Wade JC; Wade JL; Winn RJ; Wozniak AJ; Somerfield MR;
    J Clin Oncol; 2000 Oct; 18(20):3558-85. PubMed ID: 11032599
    [No Abstract]   [Full Text] [Related]  

  • 9. Pegfilgrastim lowers side-effects of chemotherapy.
    Sharma DC
    Lancet Oncol; 2004 Aug; 5(8):461. PubMed ID: 15309779
    [No Abstract]   [Full Text] [Related]  

  • 10. Colony-stimulating factors for febrile neutropenia during cancer therapy.
    Bennett CL; Djulbegovic B; Norris LB; Armitage JO
    N Engl J Med; 2013 Mar; 368(12):1131-9. PubMed ID: 23514290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colony-stimulating factors for adjunctive therapy of infections in neutropenic cancer patients.
    Mayordomo JI; Rivera F; Cortes-Funes H
    Support Care Cancer; 1995 Jan; 3(1):84-5. PubMed ID: 7535169
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic growth factors for chemotherapy-induced neutropenia.
    Yalçin S
    Cancer Invest; 1999; 17(7):555-6. PubMed ID: 10518202
    [No Abstract]   [Full Text] [Related]  

  • 14. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC
    Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recommendation for using granulocyte and granulocyte-macrophage growth factor during anti-cancer therapy in children].
    Balwierz W; Moryl-Bujakowska A; Balwierz A; Pawińska K
    Przegl Lek; 2006; 63(1):1-6. PubMed ID: 16892890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy?
    Croockewit AJ; Koopmans PP; de Pauw BE
    Clin Pharmacol Ther; 1996 Jan; 59(1):1-6. PubMed ID: 8549028
    [No Abstract]   [Full Text] [Related]  

  • 17. American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors.
    Ozer H
    Curr Opin Hematol; 1996 Jan; 3(1):3-10. PubMed ID: 9372045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The American Society of Clinical Oncology guideline program.
    Winn RF; Smith TF
    Pharm Pract Manag Q; 1996 Apr; 16(1):31-8. PubMed ID: 10157738
    [No Abstract]   [Full Text] [Related]  

  • 19. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
    Crawford J
    Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.
    Strassels SA; Dickson M; Norris LB; Bennett CL
    J Natl Cancer Inst; 2013 Aug; 105(15):1072-3. PubMed ID: 23873406
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.